Pharma access and launch review

Bring one access or launch decision that needs a clearer internal review.

This route is for market access, health economics and outcomes research, launch, medical affairs, and brand teams that need a brief for one concrete question: a coverage push, launch timing choice, account group, or evidence question with real commercial stakes.

Bring the therapy area, the decision, the decision lead, and the bottleneck. NextConsensus returns a brief that shows the evidence, the commercial stake, who needs to review it, what is still uncertain, and what would make the team revisit the recommendation. It is built to support medical, legal, regulatory, and other internal review. Keep public intake above the PHI line, and use the trust page if you want the handling rules first.

Request access or launch review See sample decision brief

Opening brief

Access review brief

120-day pilot

Team

A named pharma team working on one therapy area, one patient segment, and up to three priority accounts.

Decision

One access, launch, or evidence decision that already has visible commercial downside if it stays unresolved.

Review path

Decision lead, medical review, legal, and any committee path that has to sign off before movement.

Recourse

Pause, narrow, or re-review the recommendation if the evidence or account pattern no longer supports the move.

What comes back

One brief with stake, approvers, uncertainty, and stop conditions visible in one place.

Expansion rule

Expand only if the first brief proves useful enough to justify more work.

Buyable first step A first step a pharma team can actually buy.

Start with a named team, a concrete decision, and a clearly scoped first brief, not a broad strategy program.

Data boundary Keep public intake above the PHI line.

Start with the decision, the cost of waiting, the approval path, and the bottleneck. Move to secure handoff only if later scope truly needs sensitive material.

Read trust and handling

What the review covers

The first review stays narrow, commercial, and easy for a pharma team to buy.

The review asks whether the evidence pattern supports active review now, what delay is costing commercially, which functions and reviewers need to weigh in, what remains uncertain, and what still needs to be resolved before action is taken.

One therapy area, patient segment, or account group
One timing-sensitive access or launch question
One decision brief covering current evidence, business impact, approval path, uncertainty, review options, and what would trigger re-review

Built for one active decision, not an ongoing monitoring program.

What comes back

What the team gets back

What may be changing

Does the evidence pattern support treating this as a decision the team needs to act on now?

Business impact

What access, account movement, or launch timing downside continues while the decision stays unresolved?

Approval path

Which functions, approvers, or committees need to review the brief before the decision can move?

Uncertainty

Which assumptions are strong, which are weaker, and what would need to be true to justify moving sooner?

If the move does not hold up

What would trigger re-review, pause the move, or send the team back to the prior approach?

Next step

Proceed, narrow the review, gather missing evidence, or stop.

First engagement

A typical first engagement stays deliberately small.

The opening scope stays small enough to buy and clear enough to judge, not broad enough to turn into a strategy program or monitoring retainer.

Team Named pharma team

A named pharma team focused on a single therapy area and patient segment, with up to three priority accounts.

Brief First brief

One review cycle to assemble the draft brief, test the call, and decide whether it is ready for internal circulation.

Pilot 120-day pilot

A 120-day pilot with a clear go, narrow, or stop checkpoint at the end.

Expand Continue only if useful

Expand only if the first brief proves valuable enough to justify a longer working relationship.

It starts with one decision and expands only if the first brief proves useful.

Boundary

What is in scope and what is not.

The opening engagement should feel clear and repeatable, not improvised for each account.

In scope One brief built around one active decision.

What the evidence looked like at the time, the business stake, who needs to sign off, what remains uncertain, the recommendation, when to revisit it, and what would trigger another review. It supports medical, legal, regulatory, and other internal review rather than substituting for it.

Out of scope Not broad launch support, not open-ended outcomes or evidence packaging.

No generic monitoring retainer, no broad market landscaping, and no custom collateral program before one real decision has been reviewed.

When to use this review

Start with one live access problem.

Best when One active question with a named team and clear commercial stakes.

The review works best when the team can already point to the therapy area, account set, or patient segment involved and the delay is visible.

Not for Broad evidence monitoring without a clear decision owner.

If there is no concrete timing decision to defend internally, the work should be narrowed before the review starts.

Contact

If the timing risk is real, send a short note.

Start with the therapy area, the proposed move, the business impact, the team, who needs to review it, and the main bottleneck. You should get a short answer on fit, missing context, and whether an intro call makes sense. Do not send PHI or patient-level data in the first note.

Request access or launch review See sample decision brief